As of Dec 12
| +0.075 / +0.14%|
The 19 analysts offering 12-month price forecasts for Novozymes A/S have a median target of 46.97, with a high estimate of 63.28 and a low estimate of 39.67. The median estimate represents a -13.35% decrease from the last price of 54.21.
The current consensus among 21 polled investment analysts is to Hold stock in Novozymes A/S. This rating has held steady since December, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.